Publications & Resources

The U.S. Food and Drug Administration has granted Eli Lilly and Company an emergency use authorization for bamlanivimab to treat mild-to-moderate COVID-19 in adult and pediatric patients.

Ventilator-associated pneumonia (VAP) is serious and deadly, but good oral healthcare can substantially reduce the likelihood that individuals connected to a mechanical ventilator contract VAP.

To support policyholders as they navigate the pandemic, MLMIC has assembled a summary of predictive tools and technology to guide management and treatment of COVID-19.

Improved treatment of COVID-19 is reducing mortality rates among those hospitalized for the infection, but experts caution the virus remains dangerous.

The coronavirus continues to affect our daily lives, but there is light at the end of the tunnel. Take a look at our FAQs for dentists about the COVID-19 vaccine, trials and what it means for dental practices.

The U.S. Food and Drug Administration has approved the antiviral drug remdesivir, sold as Veklury, to treat COVID-19 patients who meet specific criteria.

Nearly all dental practices have resumed service, taking extra precautions due to the continued threat of COVID-19 and the emerging flu season. As patients returned, dentists saw the toll the pandemic was taking on teeth through an increase in stress-related oral health conditions.

Based on a series of patient testimonials, the National Institute for Health Research says that ‘long COVID’ could actually be up to four different syndromes.

As use of telehealth continues to grow, physicians are advised to consider key factors when determining whether a virtual visit is the best option for a patient.

As telehealth use continues to rise, physicians are strongly encouraged to adopt practices that can help reduce the risk of an associated medical malpractice claim.